학술논문
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Document Type
article
Author
Elizabeth M. Swisher; Tanya T. Kwan; Amit M. Oza; Anna V. Tinker; Isabelle Ray-Coquard; Ana Oaknin; Robert L. Coleman; Carol Aghajanian; Gottfried E. Konecny; David M. O’Malley; Alexandra Leary; Diane Provencher; Stephen Welch; Lee-may Chen; Andrea E. Wahner Hendrickson; Ling Ma; Prafull Ghatage; Rebecca S. Kristeleit; Oliver Dorigo; Ashan Musafer; Scott H. Kaufmann; Julia A. Elvin; Douglas I. Lin; Setsuko K. Chambers; Erin Dominy; Lan-Thanh Vo; Sandra Goble; Lara Maloney; Heidi Giordano; Thomas Harding; Alexander Dobrovic; Clare L. Scott; Kevin K. Lin; Iain A. McNeish
Source
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancers